|
Colorectal Carcinoma
|
0.420 |
Biomarker
|
disease |
BEFREE |
Oppositely, we found that one gene (LPAR1), downregulated universally in CRC tissues, was silenced in CRC tissues but highly expressed in normal colorectal tissues, which were considered to be tumor suppressor genes in CRC.
|
30395690 |
2019 |
|
Colorectal Carcinoma
|
0.420 |
Biomarker
|
disease |
CTD_human |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
|
Colorectal Carcinoma
|
0.420 |
GeneticVariation
|
disease |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
|
Colorectal Carcinoma
|
0.420 |
AlteredExpression
|
disease |
BEFREE |
In comparison, colorectal cancers expressed LPA1 mRNA at a significantly lower level (0.3-fold; P<0.05), and LPA2 mRNA at a significantly higher level (three-fold; P<0.05), as compared with normal tissues.
|
15220934 |
2004 |
|
Colorectal Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
|
Colorectal Neoplasms
|
0.400 |
GeneticVariation
|
group |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Stromal LPA1 positivity (<i>p</i> = 0.017) and stromal LPA3 positivity (<i>p</i> = 0.004) were higher in breast cancer with adipose stroma containing CD68-positive crown-like structures (CLS).
|
31035435 |
2019 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
The current report examined the extent of metastasis-induced fibrosis in breast cancer model systems, and tested the metastasis preventive efficacy and fibrosis attenuation of antagonists for LPAR1 and Idiopathic Pulmonary Fibrosis (IPF) in breast and ovarian cancer models.
|
29805748 |
2018 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Collectively, our results elucidate a new molecular pathway driving LPA-induced metastasis, thus underscoring the therapeutic potential of targeting LPA1 in patients with basal breast carcinomas.
|
26098771 |
2015 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
We have recently reported that β-arrestin2 regulates LPA(1)-mediated breast cancer cell migration and invasion, although the underlying molecular mechanisms are not clearly understood.
|
23405264 |
2013 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
To determine the relevance of this model system to human breast cancer, a cohort of breast carcinomas was stained for Nm23-H1 and EDG2 and a statistically significant inverse correlation between these two proteins was revealed (r = -0.73; P = 0.004).
|
18089805 |
2007 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
Our previous study demonstrated that lysophosphatidic acid (LPA) enhances vascular endothelial growth factor-C (VEGF-C) expression, a lymphangiogenic factor, through activating it receptors LPA1/3 in prostate cancer (PCa) cells.
|
30317243 |
2018 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
One potential mechanism for the inhibition involves negative interactions between FFA4 and LPA1, thereby suppressing responses to EGF that require LPA1 In the current study, we examined the role of LPA1 in mediating EGF and FFA4 agonist responses in two human prostate cancer cell lines, DU145 and PC-3.
|
27474750 |
2016 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.
|
24828490 |
2014 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
The results of the present study suggest that LPA, the receptor LPA(1), ERK2 and p38alpha are important regulators for prostate cancer cell invasion and thus could play a significant role in the development of metastasis.
|
17531530 |
2007 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
CTD_human |
These results suggest the possible utility of LPA(1) as a drug target to interfere with progression of prostate cancer.
|
16809448 |
2006 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
Stromal LPA1 positivity (<i>p</i> = 0.017) and stromal LPA3 positivity (<i>p</i> = 0.004) were higher in breast cancer with adipose stroma containing CD68-positive crown-like structures (CLS).
|
31035435 |
2019 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
The current report examined the extent of metastasis-induced fibrosis in breast cancer model systems, and tested the metastasis preventive efficacy and fibrosis attenuation of antagonists for LPAR1 and Idiopathic Pulmonary Fibrosis (IPF) in breast and ovarian cancer models.
|
29805748 |
2018 |
|
Mammary Neoplasms
|
0.330 |
AlteredExpression
|
group |
BEFREE |
Finally, high LPAR1 expression in basal breast tumors predicted worse lung-metastasis-free survival.
|
26098771 |
2015 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
We have recently reported that β-arrestin2 regulates LPA(1)-mediated breast cancer cell migration and invasion, although the underlying molecular mechanisms are not clearly understood.
|
23405264 |
2013 |
|
Mammary Neoplasms
|
0.330 |
Biomarker
|
group |
LHGDN |
LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells.
|
17496233 |
2007 |
|
Mammary Neoplasms
|
0.330 |
AlteredExpression
|
group |
LHGDN |
Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2.
|
18089805 |
2007 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Mammary Neoplasms
|
0.330 |
Biomarker
|
group |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |